CP
Circle Pharma, Inc.
United States · Biotech
Circle Pharma discovers macrocycle medicines for cancer and other serious diseases using its MXMO platform, which combines computational, structure-based design with synthetic chemistry to create cell-permeable compounds against difficult protein targets. Its lead programs are investigational and at discovery or preclinical stages.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series E | $92.5M | The Column Group — LeadEli Lilly and Company — ParticipantEuclidean Capital — ParticipantNextech Invest — ParticipantRA Capital Management — Participant |